NeuroSense Reports First Quarter 2023 Financial Results & Provides Business Update: Phase 2b ALS Trial Completes Enrollment, Topline Data Expected Q4 2023

/PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today...

Related Keywords

Massachusetts ,United States ,Cambridge ,Cambridgeshire ,United Kingdom ,Ghazaleh Sadri Vakili ,Linkedin ,Hospital Neuroepigenetics Lab ,Neurosense Therapeutics Ltd ,Prnewswire Neurosense Therapeutics Ltd ,Twitter ,Nasdaq ,Sense Therapeutics ,Patient Enrollment ,Participants Who Completed ,Trial Chose ,Trial Under Preparation ,Massachusetts General Hospital ,Neuroepigenetics Lab ,Improve Early Detection ,Interim Unaudited Consolidated Statements ,Neurosense ,